Menopause research has historically been underfunded relative to the number of people it affects. That’s beginning to change. Here’s what the recent science is actually finding.
For most of medical history, menopause was treated as an inevitable inconvenience to be endured rather than a biological process worth serious scientific investment. That funding gap was real — and to a significant degree, it remains. Menopause affects roughly half the global population across their lifetime, yet for decades it received a fraction of the research attention given to conditions with smaller patient populations and more powerful pharmaceutical advocates.
A confluence of factors has shifted this: increased women’s health advocacy, a generation of female researchers reaching senior positions in academia and biotech, and growing recognition that ovarian aging has systemic effects that extend well beyond reproductive function. The pace of published research in this area has accelerated meaningfully in the past five years.
What We’ve Learned About Ovarian Aging
The ovary is one of the faster-aging organs in the body. While most organs decline gradually across the lifespan, ovarian function falls sharply and early: a woman at 35 has significantly fewer viable follicles than she did at 25, and by perimenopause — typically late 40s to early 50s — that decline has accelerated further. What recent research has clarified is that this decline doesn’t just affect fertility and oestrogen levels. It has downstream effects on cardiovascular health, bone density, brain function, metabolic efficiency, and immune regulation. These connections are now better established than they were even a decade ago.
Research published in Nature Aging has identified mitochondrial function as a significant factor in ovarian aging — eggs in follicles require exceptionally high mitochondrial energy output for successful maturation, and mitochondrial efficiency in the ovary declines faster than in most other tissues. Studies using mitochondrial support compounds and senescent cell clearance have shown effects on ovarian aging in animal models. These findings are promising, but it is important to be clear: the bulk of this work remains in animal models or very early human trials. The science is genuinely interesting; clinical applications in humans are not yet established.
Separately, researchers have identified molecular pathways — including mTOR signalling and NAD+ metabolism — as regulators of follicle depletion rates. These are, in principle, targetable. Early-stage clinical trials are underway, but results that would support clinical recommendations are years away.
The Hormone Therapy Question
Hormone replacement therapy (HRT) has been the primary clinical intervention for menopausal symptoms for decades, but its use was dramatically shaped — and in the view of many researchers, distorted — by the Women’s Health Initiative study published in 2002, which reported increased risks of breast cancer and cardiovascular events in HRT users. That study led to a sharp drop in HRT prescribing that persisted for years.
Subsequent reanalysis of that data — and a substantial body of follow-on research — found that the risks reported were largely age-dependent and applied primarily to women who began HRT more than ten years after menopause onset, rather than those who started during the transition itself. The 2002 findings were never wrong exactly, but they were widely applied to a much broader population than the evidence supported.
The current consensus, reflected in updated guidance from the Menopause Society and the British Menopause Society, is that for healthy women under 60 or within ten years of menopause onset, the benefits of HRT for symptom management — and potentially for long-term cardiovascular, bone, and cognitive health — outweigh the risks for most women. That guidance has been slow to reach both patients and clinicians. The gap between what the evidence shows and what women are actually being told in clinical settings remains a documented problem.
What’s on the Horizon
Several early-stage approaches are generating scientific interest, and it is worth being precise about where they stand.
Platelet-rich plasma injections to potentially extend follicular lifespan are in clinical trials; early results are being studied but this is not an established treatment. Selective oestrogen receptor modulators with more targeted tissue profiles are in pharmaceutical development. And researchers working in the broader aging biology space are investigating whether senolytic drugs, NAD+ precursors, and mitochondrial-targeted antioxidants have specific applications in ovarian aging — none of these are ready for clinical use, and many are currently only validated in animal models.
What is available now is a better-informed conversation between women and their doctors — about HRT, about lifestyle factors that genuinely support the menopause transition, and about distinguishing what the evidence supports from what the supplement industry is marketing. The science is moving faster than it was. The gap between what the research shows and what most women are being told by their healthcare providers remains the more urgent problem.
Sources
Mosconi, L. et al. (2021). “Menopause impacts human brain structure, connectivity, energy metabolism, and amyloid-beta deposition.” Scientific Reports.
Manson, J.E. et al. (2013). “Menopausal hormone therapy and health outcomes during the intervention and extended poststopping phases of the Women’s Health Initiative randomized trials.” JAMA.
The Menopause Society (2022). Hormone Therapy Position Statement.
British Menopause Society (2023). Updated consensus statement on HRT.
Note: Animal model findings on mitochondrial interventions and ovarian aging are drawn from published research in Nature Aging and related journals (2022–2024). Human clinical applications remain investigational. Specific trial results should be verified against current clinical trial registries (ClinicalTrials.gov) for the most up-to-date status.
